EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer

Niraj Neupane, Sawyer Bawek, Sayuri Gurusinghe, Elham Moases Ghaffary, Omid Mirmosayyeb iD, Sangharsha Thapa, Carla Falkson, Ruth O'Regan, Ajay Dhakal

Cancers · 31.01.2024 · 16 (3) · 619

DOI: 10.3390/cancers16030619 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.01.2024. Verfasst von Niraj Neupane und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USA. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most common cancer among women worldwide, and estrogen receptor-positive (ER+) breast cancer accounts for a significant proportion of cases. While various treatments are available, endocrine therapies are often the first-line treatment for this type of breast cancer. However, the development of drug resistance poses a significant challenge in managing this disease. ESR1 mutations have been identified as a common mechanism of endocrine therapy resistance in ER+ breast cancer. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has shown some activity against ESR1 mutant tumors. However, due to its poor bioavailability and need for intramuscular injection, it may not be the optimal therapy for patients. Second-generation SERDs were developed to overcome these limitations. These newer drugs have improved oral bioavailability and pharmacokinetics, making them more convenient and effective for patients. Several oral SERDs are now in phase III trials for early and advanced ER+ breast cancer. This review summarizes the background of oral SERD development, the current status, and future perspectives.

Schlagwörter

Stichwörter der Autor:innen

SERDsbreast cancerendocrine therapiesestrogen receptor-positiveoralresistanceselective estrogen receptor degraders

Autor:innen und Institutionen

  • Department of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USA.
  • Department of Internal Medicine, University at Buffalo, Buffalo, NY 14203, USA.
  • Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran.
  • Westchester Medical Center, New York Medical College, Valhalla, NY 10595, USA.
  • Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.

ORCID-Profile: Omid Mirmosayyeb

Zitieren

APA

Neupane, N., Bawek, S., Gurusinghe, S., Ghaffary, E. M., Mirmosayyeb, O., Thapa, S., Falkson, C., O'Regan, R., & Dhakal, A. (2024). Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. Cancers, 16(3), 619. https://doi.org/10.3390/cancers16030619

Vancouver

Neupane N, Bawek S, Gurusinghe S, Ghaffary EM, Mirmosayyeb O, Thapa S, et al. Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. Cancers. 2024;16(3):619. doi:10.3390/cancers16030619

BibTeX
@article{Neupane2024,
  author = {Neupane, Niraj and Bawek, Sawyer and Gurusinghe, Sayuri and Ghaffary, Elham Moases and Mirmosayyeb, Omid and Thapa, Sangharsha and Falkson, Carla and O'Regan, Ruth and Dhakal, Ajay},
  title = {Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {3},
  pages = {619},
  doi = {10.3390/cancers16030619}
}
Kostenlos starten →